<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00926107</url>
  </required_header>
  <id_info>
    <org_study_id>HE 4/09</org_study_id>
    <secondary_id>2008-007925-38</secondary_id>
    <nct_id>NCT00926107</nct_id>
  </id_info>
  <brief_title>Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse</brief_title>
  <official_title>Study of the mTOR Inhibitor Temsirolimus(CCI-779) in Patients With CA125 Only Relapse of Ovarian Cancer. A Phase II Study by the Hellenic Cooperative Oncology Group.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hellenic Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the efficacy of Temsirolimus in patients&#xD;
      with ovarian cancer with CA125 only relapse after first-line platinum-based chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study ended prematurely due to the low accrual rate (24% of the expected accrual rate) in&#xD;
    the first two years of patients enrolment&#xD;
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical progression free survival.</measure>
    <time_frame>6-month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS),Survival, CA125 response rate, Safety</measure>
    <time_frame>Duration of the study</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">9</enrollment>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>Temsirolimus 25mg weekly until clinical progression</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologic proof of epithelial ovarian,fallopian or peritoneal carcinoma of the&#xD;
             following histological types:serous, endometrioid, mucinous, clear cell, low&#xD;
             differentiation.&#xD;
&#xD;
          2. Age 18 years or older&#xD;
&#xD;
          3. Patients should have received first-line platinum based chemotherapy&#xD;
&#xD;
          4. Documented CA125 progression according to GCIC criteria.&#xD;
&#xD;
          5. No evidence of measurable or evaluable disease.&#xD;
&#xD;
          6. Provision of written informed consent&#xD;
&#xD;
          7. ECOG PS 0-2&#xD;
&#xD;
          8. Life expectancy of greater than 12 weeks&#xD;
&#xD;
          9. WBC&gt;4000/μl, platelets &gt; 100,000/μl and a hemoglobin level &gt; 9.5 g/dl. Adequate&#xD;
             baseline hepatic function, defined as a total bilirubin level &lt; 2 mg/dl, SGPT and SGOT&#xD;
             &lt; 2.5 times the upper limits of normal. Creatinine &lt; 1.5 mg/dl or creatinine clearance&#xD;
             &gt; 60 ml/min.&#xD;
&#xD;
         10. All females of childbearing potential must have a negative serum or urine pregnancy&#xD;
             test obtained within 2 days prior to initiation of treatment and use effective&#xD;
             contraception during the period of therapy.&#xD;
&#xD;
         11. At least one month from the last chemotherapy administration.&#xD;
&#xD;
         12. Provision of adequate paraffin-embedded tumor tissue for translational studies&#xD;
             (optional).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other histological types (germ cell, granulose tumors etc)&#xD;
&#xD;
          2. History of atrial or ventricular arrhythmias and/or history of congestive heart&#xD;
             failure, even if medically controlled. History of clinical and&#xD;
             electrocardiographically documented myocardial infarction within the last 6 months&#xD;
             from study entry&#xD;
&#xD;
          3. Any evidence of clinically active interstitial lung disease (patients with chronic&#xD;
             stable radiographic changes who are asymptomatic need not be excluded)&#xD;
&#xD;
          4. Pre-existing motor or sensory neurotoxicity grade 2 according to the WHO criteria&#xD;
             (intolerable paresthesia and/or marked motor loss or worse)&#xD;
&#xD;
          5. History of any treatment for CA125 relapse&#xD;
&#xD;
          6. Known, severe hypersensitivity to temsirolimus or any of the excipients of this&#xD;
             product&#xD;
&#xD;
          7. Other coexisting malignancies or malignancies diagnosed within the last 5 years with&#xD;
             the exception of basal cell carcinoma or cervical cancer in situ&#xD;
&#xD;
          8. Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer&#xD;
             therapy&#xD;
&#xD;
          9. As judged by the investigator, any evidence of severe or uncontrolled systemic disease&#xD;
             (eg unstable or uncompensated respiratory, cardiac, hepatic or renal disease)&#xD;
&#xD;
         10. Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2.5&#xD;
             times the ULRR.&#xD;
&#xD;
         11. Active infection or evidence of any other significant clinical disorder or laboratory&#xD;
             finding that makes it undesirable for the patient to participate in the trial/ receive&#xD;
             protocol treatment&#xD;
&#xD;
         12. Concomitant use of Cyp3 A inducers (phenytoin, carbamazepine, rifampicin, barbiturates&#xD;
             or St John's Wort) should be avoided and as should treatment with strong CyP 3A&#xD;
             inhibitors&#xD;
&#xD;
         13. Treatment with a non-approved or investigational drug within 30 days before Day 1 of&#xD;
             trial treatment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>&quot;Alexandra&quot; Hospital, Dept. of Clinical Therapeutics, Oncology</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Attikon&quot; University Hospital, 2nd Dept. of Internal Medicine-Propaedeutic, Oncology Section</name>
      <address>
        <city>Athens</city>
        <zip>12461</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hygeia Hospital, 1st Dept. of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hygeia Hospital, 2nd Dept. of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agii Anargiri Cancer Hospital, 3rd Dept. of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chania General Hospital, Oncology Dept.</name>
      <address>
        <city>Chania</city>
        <zip>73100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ioannina University Hospital, Dept. of Medical Oncology</name>
      <address>
        <city>Ioannina</city>
        <zip>45110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Larissa University Hospital, Oncology Dept.</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Patras, Oncology Dept</name>
      <address>
        <city>Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital, 1st Dept. of Medical Oncology</name>
      <address>
        <city>Pireaus</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital, 2nd Dept. of Medical Oncology</name>
      <address>
        <city>Pireaus</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Papageorgiou&quot; General Hospital, Dept. of Medical Oncology</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>June 22, 2009</study_first_submitted>
  <study_first_submitted_qc>June 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2009</study_first_posted>
  <last_update_submitted>November 9, 2011</last_update_submitted>
  <last_update_submitted_qc>November 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

